Cargando…
MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype that accounts for approximately 15–20% of all BC cases. Cancer cell lines (CLs) provide an efficient way to model the disease. We have recently isolated a patient-derived triple-negative BC CL MFUM-BrTNBC-1 and performed a detailed...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749978/ https://www.ncbi.nlm.nih.gov/pubmed/35011679 http://dx.doi.org/10.3390/cells11010117 |
_version_ | 1784631356363374592 |
---|---|
author | Skok, Kristijan Gradišnik, Lidija Čelešnik, Helena Milojević, Marko Potočnik, Uroš Jezernik, Gregor Gorenjak, Mario Sobočan, Monika Takač, Iztok Kavalar, Rajko Maver, Uroš |
author_facet | Skok, Kristijan Gradišnik, Lidija Čelešnik, Helena Milojević, Marko Potočnik, Uroš Jezernik, Gregor Gorenjak, Mario Sobočan, Monika Takač, Iztok Kavalar, Rajko Maver, Uroš |
author_sort | Skok, Kristijan |
collection | PubMed |
description | Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype that accounts for approximately 15–20% of all BC cases. Cancer cell lines (CLs) provide an efficient way to model the disease. We have recently isolated a patient-derived triple-negative BC CL MFUM-BrTNBC-1 and performed a detailed morphological and molecular characterisation and a comprehensive comparison with three commercial BC CLs (MCF-7, MDA-MB-231, MDA-MB-453). Light and fluorescence microscopy were used for morphological studies; immunocytochemical staining for hormone receptor, p53 and Ki67 status; RNA sequencing, qRT-PCR and STR analysis for molecular characterisation; and biomedical image analysis for comparative phenotypical analysis. The patient tissue-derived MFUM-BrTNBC-1 maintained the primary triple-negative receptor status. STR analysis showed a stable and unique STR profile up to the 6th passage. MFUM-BrTNBC-1 expressed EMT transition markers and displayed changes in several cancer-related pathways (MAPK, Wnt and PI3K signalling; nucleotide excision repair; and SWI/SNF chromatin remodelling). Morphologically, MFUM-BrTNBC-1 differed from the commercial TNBC CL MDA-MB-231. The advantages of MFUM-BrTNBC-1 are its isolation from a primary tumour, rather than a metastatic site; good growth characteristics; phenotype identical to primary tissue; complete records of origin; a unique identifier; complete, unique STR profile; quantifiable morphological properties; and genetic stability up to (at least) the 6th passage. |
format | Online Article Text |
id | pubmed-8749978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87499782022-01-12 MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines Skok, Kristijan Gradišnik, Lidija Čelešnik, Helena Milojević, Marko Potočnik, Uroš Jezernik, Gregor Gorenjak, Mario Sobočan, Monika Takač, Iztok Kavalar, Rajko Maver, Uroš Cells Article Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype that accounts for approximately 15–20% of all BC cases. Cancer cell lines (CLs) provide an efficient way to model the disease. We have recently isolated a patient-derived triple-negative BC CL MFUM-BrTNBC-1 and performed a detailed morphological and molecular characterisation and a comprehensive comparison with three commercial BC CLs (MCF-7, MDA-MB-231, MDA-MB-453). Light and fluorescence microscopy were used for morphological studies; immunocytochemical staining for hormone receptor, p53 and Ki67 status; RNA sequencing, qRT-PCR and STR analysis for molecular characterisation; and biomedical image analysis for comparative phenotypical analysis. The patient tissue-derived MFUM-BrTNBC-1 maintained the primary triple-negative receptor status. STR analysis showed a stable and unique STR profile up to the 6th passage. MFUM-BrTNBC-1 expressed EMT transition markers and displayed changes in several cancer-related pathways (MAPK, Wnt and PI3K signalling; nucleotide excision repair; and SWI/SNF chromatin remodelling). Morphologically, MFUM-BrTNBC-1 differed from the commercial TNBC CL MDA-MB-231. The advantages of MFUM-BrTNBC-1 are its isolation from a primary tumour, rather than a metastatic site; good growth characteristics; phenotype identical to primary tissue; complete records of origin; a unique identifier; complete, unique STR profile; quantifiable morphological properties; and genetic stability up to (at least) the 6th passage. MDPI 2021-12-30 /pmc/articles/PMC8749978/ /pubmed/35011679 http://dx.doi.org/10.3390/cells11010117 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Skok, Kristijan Gradišnik, Lidija Čelešnik, Helena Milojević, Marko Potočnik, Uroš Jezernik, Gregor Gorenjak, Mario Sobočan, Monika Takač, Iztok Kavalar, Rajko Maver, Uroš MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines |
title | MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines |
title_full | MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines |
title_fullStr | MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines |
title_full_unstemmed | MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines |
title_short | MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines |
title_sort | mfum-brtnbc-1, a newly established patient-derived triple-negative breast cancer cell line: molecular characterisation, genetic stability, and comprehensive comparison with commercial breast cancer cell lines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749978/ https://www.ncbi.nlm.nih.gov/pubmed/35011679 http://dx.doi.org/10.3390/cells11010117 |
work_keys_str_mv | AT skokkristijan mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT gradisniklidija mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT celesnikhelena mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT milojevicmarko mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT potocnikuros mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT jezernikgregor mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT gorenjakmario mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT sobocanmonika mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT takaciztok mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT kavalarrajko mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines AT maveruros mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines |